- Home
- RIOT vs TGTX Comparison
RIOT vs TGTX Comparison
Compare RIOT & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIOT
- TGTX
- Stock Information
- Founded
- RIOT 2000
- TGTX 1993
- Country
- RIOT United States
- TGTX United States
- Employees
- RIOT N/A
- TGTX N/A
- Industry
- RIOT Retail: Computer Software & Peripheral Equipment
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- RIOT Technology
- TGTX Health Care
- Exchange
- RIOT Nasdaq
- TGTX Nasdaq
- Market Cap
- RIOT 5.2B
- TGTX 5.5B
- IPO Year
- RIOT N/A
- TGTX 1995
- Fundamental
- Price
- RIOT $15.01
- TGTX $33.70
- Analyst Decision
- RIOT Strong Buy
- TGTX Strong Buy
- Analyst Count
- RIOT 13
- TGTX 4
- Target Price
- RIOT $26.21
- TGTX $54.75
- AVG Volume (30 Days)
- RIOT 23.6M
- TGTX 2.2M
- Earning Date
- RIOT 10-30-2025
- TGTX 11-03-2025
- Dividend Yield
- RIOT N/A
- TGTX N/A
- EPS Growth
- RIOT 693.97
- TGTX N/A
- EPS
- RIOT 0.40
- TGTX 2.78
- Revenue
- RIOT $637,162,000.00
- TGTX $531,898,000.00
- Revenue This Year
- RIOT $81.11
- TGTX $82.31
- Revenue Next Year
- RIOT $16.07
- TGTX $49.05
- P/E Ratio
- RIOT $37.20
- TGTX $12.14
- Revenue Growth
- RIOT 103.62
- TGTX 100.88
- 52 Week Low
- RIOT $6.19
- TGTX $25.28
- 52 Week High
- RIOT $23.94
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- RIOT 43.32
- TGTX 58.04
- Support Level
- RIOT $12.04
- TGTX $30.15
- Resistance Level
- RIOT $14.46
- TGTX $31.45
- Average True Range (ATR)
- RIOT 1.20
- TGTX 1.24
- MACD
- RIOT -0.07
- TGTX 0.25
- Stochastic Oscillator
- RIOT 49.77
- TGTX 98.48
About RIOT Riot Platforms Inc.
Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining and Engineering. The Bitcoin Mining segment generates revenue from the Bitcoin the Company earns through its Bitcoin Mining activities. The Engineering segment generates revenue through customer contracts for custom engineered electrical products. It generates the majority of its revenue from the Bitcoin Mining segment.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.